Poor
Not Aligned
Patient Risk:
High
Summary
Most safety/clinical mechanism and several risk/indication claims are not supported by the provided label excerpts. Several dosing/administration and non-label legal/patent/brokerage claims are also unsupported.
Category Scores
Accurate Statements
Prolia is also known as denosumab.
Supported by the provided drug/active ingredient information (Prolia; active ingredient denosumab).
Prolia is a human monoclonal antibody.
No label excerpt provided to verify this; marked unsupported in the overall evaluation due to lack of excerpt support.
Prolia works by inhibiting the activity of osteoclasts.
No label excerpt provided to verify this mechanism; marked unsupported.
Prolia binds to RANKL.
No label excerpt provided to verify this mechanism; marked unsupported.
RANKL is involved in the formation and activation of osteoclasts.
No label excerpt provided to verify this mechanism; marked unsupported.
By inhibiting RANKL, Prolia reduces the activity of osteoclasts.
No label excerpt provided to verify this mechanism; marked unsupported.
By inhibiting RANKL, Prolia leads to a decrease in bone resorption.
No label excerpt provided to verify this mechanism; marked unsupported.
By inhibiting RANKL, Prolia leads to an increase in bone density.
No label excerpt provided to verify this claim.
Unsupported Statements
Prolia is used to treat osteoporosis.
Provided label excerpts do not include approved indications.
Prolia is used to treat osteoporosis in postmenopausal women.
Provided label excerpts do not include approved indications.
Prolia is used to treat osteoporosis in men at high risk of fracture.
Provided label excerpts do not include approved indications.
Prolia is used to treat bone metastases from solid tumors.
Provided label excerpts do not include approved indications.
Prolia is used to treat bone metastases from breast cancer.
Provided label excerpts do not include approved indications.
Prolia is used to treat bone metastases from lung cancer.
Provided label excerpts do not include approved indications.
Prolia is used to treat bone metastases from prostate cancer.
Provided label excerpts do not include approved indications.
Prolia is used to treat giant cell tumor of bone.
Provided label excerpts do not include approved indications.
Prolia is a human monoclonal antibody.
No labeling excerpt provided describing biologic class.
Prolia works by inhibiting the activity of osteoclasts.
No labeling excerpt provided describing mechanism of action.
Prolia binds to RANKL.
No labeling excerpt provided describing mechanism of action.
RANKL is involved in the formation and activation of osteoclasts.
No labeling excerpt provided describing mechanism of action.
By inhibiting RANKL, Prolia reduces the activity of osteoclasts.
No labeling excerpt provided describing mechanism of action.
By inhibiting RANKL, Prolia leads to a decrease in bone resorption.
No labeling excerpt provided describing mechanism of action.
By inhibiting RANKL, Prolia leads to an increase in bone density.
No labeling excerpt provided describing efficacy outcomes.
Prolia is FDA-approved for the indications listed in the text (osteoporosis, bone metastases, and giant cell tumor of bone).
Provided label excerpts do not include Indications and Usage.
Prolia has been shown to increase bone density in patients with osteoporosis.
Provided label excerpts do not include clinical study/effectiveness outcomes.
Prolia has been shown to reduce the risk of fractures in patients with osteoporosis.
Provided label excerpts do not include clinical study/effectiveness outcomes.
Prolia has been shown to improve quality of life in patients with bone metastases.
Provided label excerpts do not include clinical study/effectiveness outcomes.
Prolia can increase the risk of infections such as pneumonia.
No adverse reaction excerpt provided addressing infections.
Prolia can increase the risk of infections such as cellulitis.
No adverse reaction excerpt provided addressing infections.
Prolia can cause musculoskeletal pain including back pain.
No adverse reaction excerpt provided addressing musculoskeletal pain.
Prolia can cause musculoskeletal pain including joint pain.
No adverse reaction excerpt provided addressing musculoskeletal pain.
Prolia can cause nausea.
No adverse reaction excerpt provided addressing GI symptoms.
Prolia can cause vomiting.
No adverse reaction excerpt provided addressing GI symptoms.
Prolia is administered via subcutaneous injection every 6 months.
Provided excerpts include hypocalcemia monitoring but do not include the actual dosing schedule.
The recommended dosage of Prolia is 60 mg.
Provided excerpts do not include the dosing strength/recommended dose.
Prolia is a prescription medication.
Provided excerpts do not address prescription status.
Prolia is available in the United States through various pharmacies and healthcare providers.
Provided excerpts do not address distribution/availability.
Prolia is patented by Amgen, Inc.
Provided label excerpts do not address patents.
The Prolia patent is set to expire in 2029.
Provided label excerpts do not address patents.
According to DrugPatentWatch.com, the patent for Prolia was granted in 2008.
Provided label excerpts do not address patents or external sources.
According to DrugPatentWatch.com, the Prolia patent is scheduled to expire in 2029.
Provided label excerpts do not address patents or external sources.
Contradictions
Important Omissions
Do not provide/confirm label-supported dosing details (e.g., exact administration schedule and dose) because the provided FDA excerpt set does not include dosage interval/strength.
Importance:
Moderate
No monitoring or evaluation details beyond hypocalcemia/advanced CKD are included for the other broad adverse effects claimed (e.g., infections, musculoskeletal pain, nausea/vomiting), which are not supported by the provided excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response includes multiple unsupported safety/side-effect claims (infections, musculoskeletal pain, nausea/vomiting) and does not restrict to label-supported warning content. It also omits label-specific hypocalcemia risk mitigation details while making a hypocalcemia risk claim that is only partially supported by the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Large portions of the response are not supported by the provided FDA label excerpts (indications, mechanism, efficacy outcomes, adverse reactions, and dosing interval/strength). Several non-label patent/distribution statements are also unsupported.
Suggested Improvement
Limit claims strictly to the provided label excerpts (severe hypocalcemia in advance CKD; pre-existing hypocalcemia contraindication; correction and calcium/vitamin D supplementation; CKD-MBD evaluation; calcium monitoring frequency). Remove unsupported indications, efficacy, mechanism, and unrelated patent/availability statements unless the full FDA label excerpt supports them.